New Zealand markets close in 6 hours 56 minutes

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.7600-0.0400 (-1.43%)
At close: 04:00PM EST
2.7600 0.00 (0.00%)
After hours: 04:01PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 241.04M
Enterprise value 179.79M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.20
Price/book (mrq)5.21
Enterprise value/revenue 3.62
Enterprise value/EBITDA -3.57

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3-58.94%
S&P500 52-week change 3-15.72%
52-week high 37.3900
52-week low 32.7350
50-day moving average 33.5613
200-day moving average 34.3107

Share statistics

Avg vol (3-month) 3845.52k
Avg vol (10-day) 3415.79k
Shares outstanding 577.01M
Implied shares outstanding 6N/A
Float 870.19M
% held by insiders 11.18%
% held by institutions 156.28%
Shares short (14 Nov 2022) 42.93M
Short ratio (14 Nov 2022) 44.04
Short % of float (14 Nov 2022) 44.14%
Short % of shares outstanding (14 Nov 2022) 43.80%
Shares short (prior month 13 Oct 2022) 43.26M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin -119.34%
Operating margin (ttm)-155.53%

Management effectiveness

Return on assets (ttm)-25.69%
Return on equity (ttm)-88.86%

Income statement

Revenue (ttm)49.73M
Revenue per share (ttm)0.65
Quarterly revenue growth (yoy)-1.50%
Gross profit (ttm)-10.97M
EBITDA -75.15M
Net income avi to common (ttm)-59.35M
Diluted EPS (ttm)-1.0170
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)120.95M
Total cash per share (mrq)1.57
Total debt (mrq)59.7M
Total debt/equity (mrq)129.13
Current ratio (mrq)4.97
Book value per share (mrq)0.60

Cash flow statement

Operating cash flow (ttm)-57.8M
Levered free cash flow (ttm)-32.15M